Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 23, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - November 23, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/16/17 - "Pharmaceutical Combinations" in Patent Application Approval Process (USPTO 20170304311)
By a News Reporter-Staff News Editor at Women's Health Weekly A patent application by the inventors Hirawat, Samit; Massacesi, Cristian, filed on July 11, 2017, was made available online on November 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Novartis AG.
11/16/17 - ASCENT CHECKS PULSE OF PHARMA, EYES MORE BUYS
The company has already acquired pharmaceutical distribution companies Eastern Agencies in Mumbai and DC Agencies in Delhi and has also entered into a joint venture with Muthu Pharma Group of Chennai. Ascent Health has invested a total of Rs120 crore- Rs130 crore on these acquisitions. Ascent Health caters to about 20,000 retailers across India, ha
11/16/17 - Ascentage Pharma Announces U.S. FDA Acceptance of IND Application for Clinical Study of Novel IAP Inhibitor APG-1387 to Treat Advanced Solid Tumors and Blood Cancers
ROCKVILLE, Md., Nov. 15, 2017/ PRNewswire-USNewswire/ Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies, today announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug application for APG-1387, a novel small molecule IAP inhibitor for the.
11/16/17 - Ask The Doctors
DEAR DOCTOR: Our daughter was successfully treated for leukemia as a child, but the chemotherapy she went through was pretty brutal. Now I've read that we have the first gene therapy for cancer, which is a huge deal. Kymriah is the first gene therapy to be approved by the Food and Drug Administration.
11/16/17 - Ask the Doctors: Newly approved gene therapy a breakthrough in cancer treatment
Dear Doctor: Our daughter was successfully treated for leukemia as a child, but the chemotherapy she went through was brutal. Now, I've read that we have the first gene therapy for cancer, which is a huge deal. Kymriah is the first gene therapy to be approved by the Food and Drug Administration.
11/16/17 - Assessing User Fees Under the Biosimilar User Fee Amendments of 2017; Draft Guidance for Industry; Availability
SUMMARY: The Food and Drug Administration is announcing the availability of a draft guidance for industry entitled "Assessing User Fees Under the Biosimilar User Fee Amendments of 2017." This draft guidance concerns FDA's implementation of the Biosimilar User Fee Amendments of 2017 and certain intended changes in policies and procedures surrounding
11/16/17 - Attorney General Laxalt and 43 States Urge Repeal of a Federal Law to Address Opioid Supply
Nevada Attorney General Adam Paul Laxalt issued the following news release:. Nevada Attorney General Adam Paul Laxalt and a bipartisan coalition of 43 attorneys general sent a letter to congressional leaders urging them to repeal a 2016 federal law to hold registered drug manufacturers and distributors accountable for willfully contributing to the.
11/16/17 - Attorneys General Bondi Urges Repeal of Federal Law to Hold Drug Manufacturers, Distributors More Accountable for Opioid Oversupply
Florida Attorney General Pam Bondi issued the following news release:. Attorney General Pam Bondi joined 43 other attorneys general to send a National Association of Attorneys General policy letter to congressional leaders, urging the repeal of a 2016 federal law to restore the Drug Enforcement Administration's ability to hold drug manufacturers an
11/16/17 - Auspex Pharmaceuticals Assigned Patent for Pharmacokinetics of Deuterated Benzoquinoline Inhibitors
Auspex Pharmaceuticals, Frazer, Pennsylvania, has been assigned a patent developed by seven co-inventors for "formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2." The co-inventors are Andreas Sommer, Carlsbad, California, Chengzhi Zhang, San Diego, John Carter, Vista, California, John Arth
11/16/17 - BioCanCell Announces Updated Results from the Phase 2 Clinical Trial of BC-819 and BCG in Patients with Bladder Cancer [Tehran Times (Iran)]
-BioCanCell Ltd., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer, announced today additional final clinical trial results for its combination therapy clinical trial of BC-819, BioCanCells lead drug, together with BCG, a current therapy for bladder cancer...
11/16/17 - Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
Biohaven Pharmaceutical Holding Company Ltd. announced that it is completing enrollment today in the first of its two registrational Phase 3 clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant. Study BHV3000-301 has enrolled over 1,400 subjects since July 2017. Vlad Coric, M.D., Chief Executive Offi
11/16/17 - Cardiac Cell Therapy Safely Improves Heart Function, Upper Limb Strength in Duchenne Muscular Dystrophy Patients
The Cedars-Sinai Medical Center issued the following news release:. The cardiac progenitor cells administered to the patients were contained in CAP-1002, the lead investigational therapy under development at Capricor Therapeutics Inc.. "This is the first trial to test cell therapy to treat heart disease in patients with Duchenne muscular dystrophy
11/16/17 - Cellect Chosen Among Selected Global Leaders Presenting at Bio-Europe 2017 Conference Addressing over 3,800 Industry Specialists from Over 2,000...
Cellect Chosen Among Selected Global Leaders Presenting at Bio-Europe 2017 Conference Addressing over 3,800 Industry Specialists from Over 2,000 World Leading Companies. By a News Reporter-Staff News Editor at Gene Therapy Weekly Cellect Biotechnology Ltd., a developer of stem cell selection technology, announced that Company CEO, Dr.
11/16/17 - Cincinnati Children's Research Paves Way for Newly Approved Asthma Drug
Thanks in part to nearly two decades of research at Cincinnati Children's Hospital Medical Center, the FDA has approved benralizumab, the first drug designed to specifically deplete eosinophils as a treatment for asthma. The FDA approved benralizumab as an add-on maintenance treatment for severe asthma with eosinophil involvement.
11/16/17 - Clinical Trial Management System Market to Rake in Nearly USD 1,848.5 Million in Terms of Revenue by the End of 2019: Clinical trials, which are used for testing the efficacy and safety of a medical devices, drug, of any other therapeutic product, ar
Albany, NY 11/15/2017 According to a new market report published by Persistence Market Research "Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019" the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019,
11/16/17 - Curetis Publishes Business and Financial Update for the First Nine Months of 2017
Curetis Publishes Business and Financial Update for the First Nine Months of 2017- Preparing for expected U.S. FDA clearance decision on Unyvero System and Unyvero LRT Application- Second U.S. FDA trial initiated for Unyvero IJI Application Amsterdam, the Netherlands, and Holzgerlingen, Germany, November 16, 2017; published at 02:00 a.m. EDT- Curet
11/16/17 - Dauphin Clinic Pharmacy - Analyzes the Impact of Technology on Pharmacy Operations
DAUPHIN, MANITOBA, CANADA/ ACCESSWIRE/ November 16, 2017/ The Canadian pharmaceutical industry is the tenth largest in the world. For example, PricewaterhouseCoopers estimates that industry innovation in the United States will generate US $160 billion by 2025, including US $11 billion for data firms alone. Dauphin Clinic Pharmacy recognizes that ne
11/16/17 - Drug firm founder indicted in opioid conspiracy due in court
BOSTON The founder of a pharmaceutical company charged with leading a conspiracy to bribe doctors to prescribe a powerful opioid pain medication for people who didn't need it is due in court in Massachusetts.
11/16/17 - Drug firm founder pleads not guilty to opioid bribe scheme
The founder of a pharmaceutical company charged with leading a conspiracy to bribe doctors to prescribe a powerful opioid pain medication for people who didn't need it is due in court in Massachusetts. John Kapoor of Insys Therapeutics Inc. was arrested in Arizona last month and is expected to make his first appearance in Boston's federal courthous
11/16/17 - Drug firm founder pleads not guilty to opioid conspiracy
The founder of a pharmaceutical company charged with leading a conspiracy to bribe doctors to prescribe a powerful opioid pain medication for people who didn't need it is due in court in Massachusetts. John Kapoor of Insys Therapeutics Inc. was arrested in Arizona last month and is expected to make his first appearance in Boston's federal courthous
11/16/17 - Duke Cancer Institute Reports Findings in Breast Cancer (Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and...
By a News Reporter-Staff News Editor at Women's Health Weekly Investigators discuss new findings in Oncology- Breast Cancer. According to news reporting out of Durham, North Carolina, by NewsRx editors, research stated, "In 2015, the biosimilar filgrastim EP2006 became the first biosimilar approved by the US Food and Drug Administration for comme
11/16/17 - FDA Nod For Breast Cancer Combo Therapy, RARE Scripts History, EDAP Disappoints
LONDON- Today's Daily Dose brings you news about FDA approval of Faslodex-Verzenio combo for advanced breast cancer; EDAP's disappointing Q3 results; upcoming clinical trial catalysts of TapImmune, and the first drug to be greenlighted for Sly syndrome. The FDA has approved AstraZeneca plc's FASLODEX in combination with Lilly' s* Abemaciclib for th
11/16/17 - Fighting Disease and World Hunger: New PET/CT Scanner Opens at the University of Missouri
The University of Missouri issued the following news release:. Housed in a new imaging core in the College of Veterinary Medicine, the combination positron emission tomography scanner and computed tomography scannerthe PET/CT systemwill improve accuracy and speed in the diagnosis and treatment of cancer, cardiovascular disorders and Lou Gehrig'
11/16/17 - Global Allergy Immunotherapy Market Competitive Research & Emerging Companies
Brooklyn, NY 11/15/2017 Qyresearchreports include new market research report "Global Allergy Immunotherapy Market Size, Status and Forecast 2022" to its huge collection of research reports. This report studies the global Allergy Immunotherapy market, analyzes and researches the Allergy Immunotherapy development status and forecast in United S
11/16/17 - Global Dietary supplements market is expected to grow with a CAGR between 5.5% and 6.0% from 2017 to 2023
The study on Dietary supplements market covers the analysis of regions such as North America, Europe, Asia Pacific, and Rest of the World. Among the geographies Asia Pacific dominated the world market. Moreover, Africa and Middle East is expected to grow at a highest CAGR over the forecast period due to changing lifestyle of the consumers. The repo
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415